These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8999328)

  • 41. Coronary risk assessment methods and cholesterol lowering.
    Smith GD; Ebrahim S
    Lancet; 1999 Mar; 353(9158):1097. PubMed ID: 10199372
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness of statin medications.
    Kaplan RM; Golomb BA
    Am Psychol; 2001 Apr; 56(4):366-7. PubMed ID: 11330239
    [No Abstract]   [Full Text] [Related]  

  • 43. More on PROSPER.
    Baztán JJ; Hornillos M; Rodríguez-Mañas L
    Lancet; 2003 Mar; 361(9363):1135; author reply 1136. PubMed ID: 12672345
    [No Abstract]   [Full Text] [Related]  

  • 44. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An opposing view.
    Zweig S
    J Fam Pract; 1988 Jun; 26(6):670-5. PubMed ID: 3132527
    [No Abstract]   [Full Text] [Related]  

  • 46. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ;
    Atheroscler Suppl; 2004 Oct; 5(3):91-7. PubMed ID: 15531281
    [No Abstract]   [Full Text] [Related]  

  • 47. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 48. [Broader indication for treatment with statins; the 'heart protection study'].
    Stalenhoef AF; Stuyt PM
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1921-3. PubMed ID: 12404905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New cholesterol drugs are overpriced, independent analysis finds.
    McCarthy M
    BMJ; 2015 Sep; 351():h4864. PubMed ID: 26359445
    [No Abstract]   [Full Text] [Related]  

  • 50. Which lipid-lowering agent should be used first?
    Rutledge DR
    Clin Pharm; 1991 Dec; 10(12):943-5. PubMed ID: 1773584
    [No Abstract]   [Full Text] [Related]  

  • 51. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
    Freemantle N; Mason J
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9583930
    [No Abstract]   [Full Text] [Related]  

  • 52. A switch in time saves more than nine. Two popular statins, Pravachol and Zocor, go generic this summer, paving the way for significant savings.
    Harv Heart Lett; 2006 May; 16(9):1-2. PubMed ID: 16688877
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of pharmacological interventions on progression of coronary atherosclerosis].
    Navarro A
    Rev Esp Cardiol; 1996 May; 49(5):389-90. PubMed ID: 8744396
    [No Abstract]   [Full Text] [Related]  

  • 54. Should we treat hypercholesterolaemia in patients over 65?
    Oliver MF
    Heart; 1997 Jun; 77(6):491-2. PubMed ID: 9227285
    [No Abstract]   [Full Text] [Related]  

  • 55. Non-lipid properties of statins.
    Kendall MJ; Toescu V
    J Clin Pharm Ther; 1999 Feb; 24(1):3-5. PubMed ID: 10319901
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost effectiveness of lowering cholesterol. Costs in general practice.
    Robertson M
    BMJ; 1996 Nov; 313(7065):1143-4. PubMed ID: 8916711
    [No Abstract]   [Full Text] [Related]  

  • 57. To test or not to test, that is the question.
    Hlatky MA
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):207-8. PubMed ID: 24619317
    [No Abstract]   [Full Text] [Related]  

  • 58. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis.
    Vieira JL; Portal VL; Moriguchi EH
    Arq Bras Cardiol; 2001 May; 76(5):409-18. PubMed ID: 11359190
    [No Abstract]   [Full Text] [Related]  

  • 59. Prevention of coronary heart disease in Scotland.
    Dunnigan MG
    BMJ; 1990 Jun; 300(6739):1583. PubMed ID: 2372628
    [No Abstract]   [Full Text] [Related]  

  • 60. Asymptomatic hypercholesterolaemia.
    Gray DP; Steele R; Sweeney K; Evans P
    BMJ; 1991 Apr; 302(6783):1022. PubMed ID: 2039883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.